Physician Directory

Arie Belldegrun, MD, FACS

Professor of Urology; Founder, UCLA Kidney Cancer Program. Dr. Belldegrun also holds the Roy and Carol Doumani Chair in Urologic Oncology and serves as the Director of the Urologic Oncology Fellowship Program at UCLA. His surgical expertise encompasses all aspects of urologic oncology, including kidney cancer, prostate cancer, bladder cancer and testicular cancer. He has authored over 400 peer-reviewed publications, books, and book chapters in the area of localized and advanced kidney and prostate cancer. Dr. Belldegrun is a world-renown expert in complicated kidney cancer surgeries, and has unique expertise in a variety of surgical approaches to small kidney tumors including open, laparoscopic, and robotic partial nephrectomy and cryotherapy. Dr. Belldegrun's research lab at UCLA focuses on the development of personalized cancer immunotherapy and targeted cancer vaccines for the treatment of kidney cancer. More >

Paul C. Boutros, PhD

Professor of UCLA Urology, Director of Cancer Data Science for the UCLA Jonsson Comprehensive Cancer Center, Associate Director of Cancer Informatics at the Institute for Precision Health, Professor of Human Genetics, and an integral member of the Institute of Urologic Oncology and the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at UCLA. Boutros received his undergraduate degree in Chemistry from the University of Waterloo, his doctorate in Medical Biophysics from the University of Toronto, and his Executive MBA from the Rotman School of Management, University of Toronto. Dr. Boutros, an internationally acclaimed cancer genomics researcher, will lead the cancer center’s efforts to use big data to optimize treatments for patients.

Andrew Goldstein, PhD

Assistant Professor-in-Residence of Urology, David Geffen School of Medicine at UCLA
Assistant Professor-in-Residence of Molecular, Cell and Developmental Biology UCLA College, Life Sciences

Dr. Goldstein earned his Bachelor of Arts in Biochemistry and Molecular Biology from Dartmouth College and his PhD in Molecular Biology from UCLA in the laboratory of Dr. Owen Witte. He went on to become the inaugural Fellow of the Broad Stem Cell Research Center at UCLA focusing on epithelial stem cell and cancer biology as an Assistant Researcher in the Departments of Urology and Molecular & Medical Pharmacology. Dr. Goldstein’s research is focused on investigating the cell-types, signaling pathways and microenvironmental cues that influence epithelial progenitor cells and promote tumorigenesis and treatment-resistance. The long-term goals of his work are to investigate the cellular and molecular mechanisms that contribute to cancer initiation, progression and treatment-resistance, particularly in prostate cancer. In addition to joining the scientific team of the UCLA Institute of Urologic Oncology and UCLA Prostate Cancer Program, Dr. Goldstein joins the faculty in the UCLA Department of Molecular, Cell and Developmental Biology.

Nestor Gonzalez-Cadavid, PhD

Adjunct Professor, Urology, Director, Urology Research Laboratory LABioMed-Harbor/UCLA, Professor, Endocrinology, Charles Drew University. Consecutive PhDs, Biochemistry, University of Buenos Aires and London. Professor of Biochemistry, Cell Biology, Central University of Venezuela, Visiting Professor/scholar, MIT, Caltech, City of Hope, UCLA. His current research interests focus on the modulation of stem cell differentiation by nitric oxide/cGMP, and myostatin, and its application to the therapy of erectile dysfunction, diabetic nephropathy, urogenital disease associated with tissue fibrosis. Funded by NIH, Department of Defense, and other agencies.

David A. Haake, MD

Dr. David Haake is a graduate of Harvard University and the New York University School of Medicine. He received his internal medicine and infectious diseases training at the UCLA Center for Health Sciences. He is currently a staff infectious diseases specialist at the Greater Los Angeles VA Healthcare System. His laboratory is developing electrochemical biosensors for rapid identification and antibiotic susceptibility testing of uropathogens. The "urosensor" assay can detect as few as 1 bacterium per sensor in less than 30 minutes. Rapid detection of drug-resistant bacterial pathogens would revolutionize treatment of urinary tract infections by enabling personalized antibiotic therapy. More >

Christopher King, MD, PhD

Dr. Christopher King PhD-MD is Associate Professor of Radiation Oncology & Urology at UCLA. He obtained his PhD in Astrophysics from Yale and his MD from Boston University. He completed his residency in Radiation Oncology at Yale and a research fellowship at Tufts. He was faculty at Stanford for nine years before joining UCLA in 2009. His areas of clinical and research interests are GU cancers (prostate, bladder, testicular and kidney) and primarily prostate cancer. His expertise ranges from the technical aspects of radiotherapy, the radiobiology of prostate cancer, the pathological and clinical factors associated with the optimal selection of treatment in both the primary and post-operative setting, and the imaging of prostate cancer (PET, CT, MRI). More >

Amar U. Kishan, MD

Assistant Professor in Radiation Oncology. Dr. Kishan graduated from the University of California, Berkeley with dual Bachelor of Arts degrees in Molecular and Cell Biology and Public Health. He earned his medical degree from Harvard Medical School, where he graduated magna cum laude from the joint Harvard-MIT Health Sciences and Technology Program. During medical school, he was awarded a Howard Hughes Medical Institute Fellowship to study tumor metabolism in the laboratory. He subsequently completed his internship training at Scripps Mercy Hospital in San Diego, where he was recognized as the H.H. Jones Intern of the Year. He then completed his residency training in radiation oncology at UCLA. He specializes in the utilization of radiation to treat genitourinary malignancies (particularly cancers of the prostate and bladder), as well as malignancies of the head and neck and central nervous system.

Sandy Ting Liu, MD

Clinical Instructor in Medicine, Hematology-Oncology. Dr. Liu completed her hematology/oncology fellowship at UCLA and Internal Medicine residency at Cedars-Sinai Medical Center. She earned her medical degree from George Washington University in Washington D.C. and her bachelors of science in biology at University of Southern California. Dr. Liu practices general hematology and oncology and specializes in genitourinary (GU) cancers. Dr. Liu is passionate about advancing the field of cancer treatment and is involved in clinical trials, with research interests in immunotherapy and drug development. Liu is on staff at Ronald Regan UCLA Medical Center, Santa Monica UCLA Hospital and Providence Tarzana Medical Center.

Nicholas G. Nickols, MD, PhD

Assistant Professor-in-Residence in Radiation Oncology. Dr. Nickols received his M.D. from UCLA and Ph.D from the California Institute of Technology through the UCLA-Caltech Medical Scientist Training Program and completed his residency training in Radiation Oncology at UCLA. He specializes in radiotherapy for prostate cancer. He has conducted extensive basic science research on the optimization of small-molecule transcription modulators for prostate cancer. He conducts prospective clinical-translational trials for localized high-risk and metastatic prostate cancer patients. More >

Steven Raman, MD

Dr. Steven Raman is a Professor of Radiology and Urology and is an expert in Urological Radiology, having published over 75 papers, 100 abstracts and several book chapters in this field. He has been the founding member of the UCLA Prostate Imaging Group, whose members include physicians and scientists dedicated to advancing the field of prostate imaging. Dr. Raman believes that MR imaging the best non-invasive solution for finding the most aggressive prostate cancer. More >

Jonathan Said, MD

Dr. Jonathan Said is Professor of Pathology and Urology at the David Geffen School of Medicine and Chief of Anatmic and Surgical Pathology at UCLA Medical Center. He is an expert in the pathology diagnosis of urologic diseases, and has published extensively on neoplastic diseases of the kidney and prostate. More >

Christopher Tarnay, MD

Associate Professor in the Department of Obstetrics & Gynecology and the Department of Urology. As a urogynecologist, he focuses on the gynecological approach to urinary incontinence, pelvic organ prolapsed, and vaginal reparative surgery. Each year, Dr. Tarnay travels to Uganda, Africa to help lead a team of doctors and nurses, providing expertise and education to local physicians in an effort to reduce maternal deaths and treat one of the most debilitating consequences to childbirth, urinary fistulae. More >

Lily Wu, MD, PhD

Faculty member, Urology since 1998. Graduated, member of the inaugural class of Medical Scientist Training Program (M.D., Ph.D. program). Her education training ranges from clinical disciplines such as pediatrics and hematology/oncology to molecular and cellular fields such as adenovirus biology, transcription regulation, and gene therapy. Besides her research endeavors, a major part of her effort involves mentoring students at all levels, from undergraduates, graduate, postdoctoral fellows to clinical residents.

Huihui Ye, MD, MS

Associate Clinical Professor of Urology and Chief of Genitourinary Pathology. Dr. Ye received her medical degree from the Zhejiang University School of Medicine in China. She completed her residency in Anatomic Pathology and Clinical Pathology at New York University Medical Center. Before coming to UCLA, Dr. Ye practiced Anatomic Pathology and served as Director of Genitourinary Pathology in the Department of Pathology at Beth Israel Deaconess Medical Center. She was Assistant Professor at Harvard Medical School. Dr. Ye's research focuses on the interplay of genetics and tumor microenvironment of genitourinary cancer including prostate cancer and renal cell carcinoma.

Gang Zeng, PhD

Associate Professor in Urologic Oncology and Member of the Jonsson Comprehensive Cancer Center. His current work is focused on cancer immunodiagnosis, immunotherapy, and prostate cancer stem cell biology.